Oncolytics Biotech (ONCY) Non-Current Assets (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Non-Current Assets of $738000.0 for Q4 2025, down 21.42% year-over-year from $939194.1 in Q4 2024, and up 0.96% quarter-over-quarter from $730994.8 in Q3 2025.
Oncolytics Biotech (ONCY) Non-Current Assets (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Non-Current Assets for 17 consecutive years, with $738000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 21.42% year-over-year to $738000.0; the TTM figure through Dec 2025 stood at $3.1 million (down 22.52% YoY), while the FY2025 annual figure was $738000.0, down 22.99% from the prior year.
- Non-Current Assets climbed to $738000.0 in Q4 2025 per ONCY's latest filing, from $730994.8 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.2 million in Q4 2022 and bottomed at $475244.5 in Q4 2023.
- Historically, Non-Current Assets has averaged $786438.5 across 5 years, with a median of $756148.0 in 2021.
- Annual changes were most pronounced in 2023 — Non-Current Assets plunged 60.9% — and 2024, when it soared 97.62%.
- Oncolytics Biotech's Non-Current Assets stood at $774296.0 in 2021, then soared by 56.99% to $1.2 million in 2022, then plunged by 60.9% to $475244.5 in 2023, then jumped by 97.62% to $939194.1 in 2024, then fell by 21.42% to $738000.0 in 2025.
- Business Quant data shows ONCY's Non-Current Assets at $738000.0 in Q4 2025, $730994.8 in Q3 2025, and $778006.1 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 18.06 Bn |
| 10 | Oncolytics Biotech | 96.99 Mn | 96.99 Mn | - | 602,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 602,000.00 |
| Dec 31, 2025 | 738,000.00 |
| Sep 30, 2025 | 730,994.81 |
| Jun 30, 2025 | 778,006.07 |
| Mar 31, 2025 | 846,753.52 |
| Dec 31, 2024 | 939,194.07 |
| Sep 30, 2024 | 988,889.05 |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 475,244.49 |
| Sep 30, 2023 | 560,939.71 |
| Jun 30, 2023 | 722,863.34 |
| Mar 31, 2023 | 789,256.02 |
| Dec 31, 2022 | 1.22 Mn |
| Sep 30, 2022 | 577,901.25 |
| Jun 30, 2022 | 652,469.46 |
| Mar 31, 2022 | 718,982.35 |
| Dec 31, 2021 | 774,296.02 |
| Sep 30, 2021 | 794,472.86 |
| Jun 30, 2021 | 708,077.77 |